Stringent control of the NF-kB and type I interferon signaling pathways is critical to effective host immune responses, yet the molecular mechanisms that negatively regulate these pathways are poorly understood. Here, we show that NLRC5, a member of the highly conserved NOD-like protein family, can inhibit the IKK complex and RIG-I/MDA5 function. NLRC5 inhibited NF-kB-dependent responses by interacting with IKKa and IKKb and blocking their phosphorylation. It also interacted with RIG-I and MDA5, but not with MAVS, to inhibit RLR-mediated type I interferon responses. Consistent with these observations, NLRC5-specific siRNA knockdown not only enhanced the activation of NF-kB and its responsive genes, TNF-a and IL-6, but also promoted type I interferon signaling and antiviral immunity. Our findings identify NLRC5 as a negative regulator that blocks two central components of the NF-kB and type I interferon signaling pathways and suggest an important role for NLRC5 in homeostatic control of innate immunity.
INTRODUCTION
The innate immune response, elicited through the detection of pathogen-associated molecular patterns (PAMPs), provides the first line of defense against invading microorganisms. PAMP recognition depends on several classes of pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) Honda and Taniguchi, 2006; Inohara et al., 2005; Medzhitov, 2007; Meylan et al., 2006; Ting et al., 2006) . Activation of most TLRs leads to the recruitment of a common adaptor, MyD88, and in turn to a series of downstream signaling events that culminate in NF-kB activation Chen, 2005; Hayden and Ghosh, 2008) . By contrast, activation of RLRs (RIG-I and MDA5) by double-and single-stranded RNAs or certain viruses (Hornung et al., 2006; Kato et al., 2006; Pichlmair et al., 2006) results in recruitment of the MAVS protein (mitochondrial antiviral signaling; also called VISA, IPS-1 and Cardif), which further activates the downstream signaling molecules TBK1/IKKi and IRF3 for type I interferon responses, as well as IKK molecules for NF-kB activation (Meylan et al., 2006) . Besides their roles in innate immunity and inflammation, TLR-mediated signaling pathways have been shown to play an important role in the control of regulatory T cell function (Liu et al., 2006; Peng et al., 2005 Peng et al., , 2007 Sutmuller et al., 2006) .
Because uncontrolled immune responses can be harmful, even fatal, to the host (Liew et al., 2005) , NF-kB activation and type I interferon signaling must be tightly regulated to maintain immune balance in the organism. Despite the importance of the IKK complex as a central transducer of signaling from various stimuli, leading to the activation of the NF-kB pathway, and of RLRs as critical receptors in type I interferon signaling (Chen, 2005; Honda and Taniguchi, 2006) , the molecular mechanisms responsible for IKK activation and RLR-mediated signaling remain poorly understood.
NLRs represent a large family of intracellular PRRs that are characterized by a conserved nucleotide-binding and oligomerization domain (NOD) and a leucine-rich repeat (LRR) region, and are involved in the activation of diverse signaling pathways Inohara et al., 2005; Meylan et al., 2006) . Several NLRs, such as NOD1, NOD2 and NALP3, have been extensively studied and shown to activate signaling pathways once they encounter relevant PAMPs Chen, 2005; Inohara et al., 2005; Meylan et al., 2006) . NALP3 inflammasome, for example, functions as a crucial component in the adjuvant effect of aluminum and asbestos (Dostert et al., 2008; Eisenbarth et al., 2008) . More recently, NLRX1 was demonstrated to function as a mitochondrial protein that interacts with the mitochondrial adaptor MAVS to inhibit the RIG-I-mediated signaling pathway and triggers the generation of reactive oxygen species as well (Moore et al., 2008; Tattoli et al., 2008) . These studies suggest that understanding the function and mechanisms of these innate immune receptors or regulators may aid in developing more effective strategies for the immunological treatment of inflammation-associated diseases Wang et al., 2008) .
Given that the NLR protein family is involved in many biological processes and functions as proinflammatory receptors as well as negative regulators, we hypothesized that some NLR members may play a critical regulatory role in the control of NF-kB and type I interferon signaling. Here we report the identification of NLRC5 as a potent negative regulator of NF-kB and IRF3 activation. It strongly inhibits NF-kB-dependent responses by interacting with IKKa and IKKb and blocking their phosphorylation. It also interacts with RIG-I and MDA5, but not with MAVS, to potently inhibit RLR-mediated type I interferon responses. As a key negative regulator of NF-kB and type I interferon signaling, NLRC5 may serve as a useful target for manipulating immune responses against infectious or inflammation-associated diseases, including cancer.
RESULTS

Molecular Cloning and Characterization of NLRC5
As a member of the NLR protein family, NLRC5 contains a CARD-like domain, a central NOD domain and a large LRR (E) Immunoblot analysis of mNLRC5 protein expression after LPS stimulation or VSV-eGFP infection (left panel). The relative protein levels of mNLRC5 were quantified by the band density scanning of western blot images and plotted against time (hr) after LPS treatment or VSV infection (right panel). (F) Both wild-type and MyD88-deficient macrophages were treated with LPS, and mNLRC mRNA expression was determined by real-time PCR analysis. See also Figure S1 . region ( Figure 1A ), but its biological function remains unknown (Chen et al., 2009; Dowds et al., 2003) . To determine the function of NLRC5, we cloned full-length human and murine NLRC5 complementary DNAs (cDNAs) by rapid amplification of cDNA ends (RACE) ( Figure 1A ). There was a 64% amino acid sequence identity between the human and murine proteins. Expression of both HA-tagged NLRC5 and mNLRC5 was demonstrated by western blotting with an anti-HA antibody (Figure 1B) . Both human and murine NLRC5 mRNAs were strongly expressed in spleen, thymus, and lung ( Figure 1C ), suggesting that this molecule is biologically conserved in these tissues.
To further demonstrate the protein expression of NLRC5 in different cell types, we generated polyclonal antibodies against endogenous NLRC5 and mNLRC5 (Figures S1A-S1E available online), which readily detected these proteins in human HEK293T (293T) cells, human THP1 cells or mouse RAW264.7 cells ( Figure S1F ). To determine whether NLRC5 expression could be regulated in response to TLR stimulation or virus infection, we treated RAW264.7 cells with LPS, intracellular poly(I:C), or infection with vesticular stomatitis virus-enhanced green fluorescent protein (VSV-eGFP), which are known to activate the NF-kB or type I IFN pathway (Yoneyama and Fujita, 2009 ). Real-time PCR and western blot analyses revealed strong upregulation of mNLRC5 at both the mRNA and protein levels, which peaked at 6 hr after LPS treatment ( Figures 1D and 1E and Figure S1G ). In contrast, we observed only a weak increase of mNLRC5 mRNA and little or no change in mNLRC5 protein after intracellular poly(I:C) treatment or VSV infection ( Figures 1D and 1E ), consistent with a previous study showing that VSV infection is a weak NF-kB inducer (Ishikawa and Barber, 2008) . To further explore the mechanisms by which NLRC5 is regulated, we performed similar experiments with wild-type and MyD88 knockout (KO) macrophages and found that upregulation of mNLRC5 was completely abolished when MyD88 KO macrophages were stimulated with LPS ( Figure 1F ), indicating that the expression of mNLRC5 itself is controlled by the NF-kB signaling pathway.
To determine the cellular localization of NLRC5, we transfected 293T cells with NLRC5-GFP fusion DNA and found that NLRC5-GFP was present in the cytoplasm, but not in the nucleus or mitochondria (Figures S1H-S1I), suggesting that NLRC5 is a cytosolic protein. No change in the cellular localization of NLRC5 was observed after LPS treatment (Figures S1I-S1K).
NLRC5 Is a Potent Negative Regulator of NF-kB Activation Induced by TLR Ligands
To determine whether NLRC5 is involved in TLR-and/or cytokine-mediated NF-kB activation, we transfected 293T or 293T/TLR4 cells with NF-kB-luc reporter DNA, with or without (E) Human THP-1 cells and murine embryonic fibroblasts (MEF) were transfected with the NF-kB-luc reporter plasmid, together with (or without) NLRC5 or mNLRC5 plasmid, and then analyzed for NF-kB-dependent luciferase activity after LPS treatment (***p < 0.001). See also Figure S2 . the NLRC5 plasmid, and then treated them with interleukin (IL)-1b, TNF-a or LPS. Results in Figure 2A show that NLRC5 potently inhibited NF-kB activation induced by IL-1b, TNF-a or LPS. We next sought to identify potential signaling molecules that activated the NFkB-luc reporter. Expression of MyD88, TRAF6, IKKa, or IKKb strongly induced NF-kB-luc activity, but such activity was inhibited when NLRC5 was cotransfected at increasing concentrations ( Figure 2B ). In contrast, NLRC5 did not inhibit p65-mediated NF-kB-luc activity, suggesting that it may interact with IKK signaling molecules upstream of p65 to block NF-kB activation ( Figure 2B ). The control plasmids NOD1 and NOD2 enhanced rather than inhibited NF-kB activity ( Figure 2C ), consistent with previous studies (Inohara et al., 1999; Ogura et al., 2001) .
Since LPS can also activate the type I IFN pathway through an adaptor TRIF molecule, we asked whether NLRC5 can inhibit LPS-induced IFN-b-luc activity (which requires cooperation between IRF3 and NF-kB activation) or interferon-stimulated response element (ISRE)-luc activity (which requires IRF3 activation only) (Zhong et al., 2008) . Functional assays showed that NLRC5 inhibited LPS-or TRIF-induced NF-kB-luc and IFN-bluc activities, but had no effects on ISRE-luc activity (Figures S2A and S2B) . Further experiments demonstrated that NLRC5 strongly inhibited R848-induced NF-kB-luc activity and weakly inhibited IFN-b-luc activity, but did not inhibit ISRE-luc activity ( Figure S2C ). Thus, NLRC5 strongly inhibits NF-kB activation induced by different TLR ligands and weakly blocks IFN-b activation mainly due to its requirement for NF-kB activity, but has no apparent effect on ISRE activity.
To determine whether the observed NLRC5-mediated inhibition of NF-kB-luc activity is associated with endogenous NF-kB activity, we performed experiments with a gel-mobility shift assay. IKKb expression allowed endogenous NF-kB to bind to the biotin-HRP-labeled DNA with NF-kB binding sites, but this activity was completely inhibited when NLRC5 was cotransfected. However, NLRC5 failed to inhibit p65-mediated NF-kB activation ( Figure 2D ), consistent with results obtained with the NF-kB-luc reporter assay. To substantiate these findings, we found that like its human homolog, mNLRC5 strongly inhibited NF-kB activation by MyD88, TRAF6, IKKa and IKKb, but not by p65 ( Figure S2D ). Moreover, NLRC5-or mNLRC5-mediated NF-kB inhibition in 293T cells could be extended to THP-1 cells and murine embryonic fibroblasts (MEFs) ( Figure 2E ). Taken together, these results suggest that NLRC5 functions as a negative regulator of NF-kB activation induced by TNF-a, IL-1b, LPS or by their downstream signaling molecules, and that its biological function is conserved between humans and mice as well as among multiple cell types. Figure 3A) . Notably, NLRC5 did not interact with either TAK1 or MEKK3 upstream of IKK ( Figure S3A ). To further test whether NLRC5 can interact with endogenous IKKa/b, we immunoprecipitated 293T cell lysates with an isotype IgG or anti-NLRC5 antibody, followed by western blot analysis with the anti-IKKa/b, anti-NEMO or anti-NLRC5 antibody. As shown in Figure 3B , the IKKa/b, but not NEMO, could be detected in the anti-NLRC5 or anti-mNLRC5-immunoprecipitants. Such an interaction between NLRC5 and IKKa/b was also observed when anti-IKKa/b and anti-NEMO antibodies were used for immunoprecipitation ( Figure S3B ). These results suggest that NLRC5 can interact with IKKa/b, but not with NEMO, under physiological conditions.
NLRC5
Since IKKa/b generally forms a complex with NEMO, a key question is whether there are two distinct complexes in unstimulated cells: IKKa/b/NEMO and IKKa/b/NLRC5. To address this issue, we used different antibodies (anti-IKKa, anti-Flag and anti-NEMO) to immunoprecipitate the IKK complexes containing either NLRC5 or NEMO, and then determined the components of their complexes. We found NEMO and NLRC5 in the anti-IKKa immunoprecipitants, NLRC5 and IKKa/b (but not NEMO) in the anti-Flag-NLRC5 immunoprecipitants, and IKKa/b and NEMO (but not NLRC5) in the anti-NEMO immunoprecipitants (Figure S3C) , suggesting that the IKKa/b/NEMO and IKKa/b/ NLRC5 complexes coexist in unstimulated cells. To definitively demonstrate the presence of two distinct complexes, we fractionated cell extracts of RAW264.7 on a size-exclusion column (HiPrep 16/60 Sephacryl S-300 HR). Immunoblotting of fractions collected from chromatography showed that IKKa/b mainly coeluted with NEMO in fractions 22-31 (molecular mass about 700 kDa) ( Figure 3C ), consistent with a previous report (Rothwarf et al., 1998) . In contrast, NLRC5 mainly eluted in fractions 15-18 (molecular mass about 1100 kDa), which also contained IKKa/ b but no NEMO ( Figure 3C ), suggesting that NLRC5 forms a larger complex with IKKa/b than previously reported for the IKKa/b/NEMO complex, thus confirming the coexistence of IKKa/b/NLRC5 and IKKa/b/NEMO complexes in unstimulated cells.
To determine the dynamics of NLRC5 interaction with IKKa/ b after stimulation, we treated RAW264.7 cells with LPS, collected them at different time points and performed immunoprecipitation and western blot analyses. The interaction between NLRC5 and IKKa/b was reduced at 30 min, but was restored at 60 min after LPS stimulation ( Figure S4A ). This oscillating pattern of interaction correlated inversely with IKK phosphorylation (p-IKK) during the first 60 min posttreatment and then diminished or even disappeared after 2 hr of treatment (Figures S4A-S4C), suggesting that the negative regulatory activity of NLRC5 is signal-dependent, but is not affected exclusively by protein concentration.
NLRC5 Competes with NEMO for IKKa/IKKb and Inhibits Their Phosphorylation and Kinase Activity
We next tested whether NLRC5 and NEMO compete each other for binding to IKKa/b. 293T cells were transfected with a fixed concentration of Flag-NLRC5 and HA-IKKb DNAs, together with increasing concentrations of HA-NEMO DNA. Coimmunoprecipitation and immunoblot revealed that the binding between NLRC5 and IKKb was markedly decreased with increasing concentrations of NEMO ( Figure 3D ). Although the phosphorylation and kinase activity of IKKa/b could be detected in the IKKa/b/NEMO complex after LPS stimulation, they decreased with increasing amounts of transfected NLRC5. There were no detectable phosphorylation and kinase activity of IKKa/b in the IKKa/b/NLRC5 complex ( Figure 3E ). Importantly, increasing amounts of NLRC5 had more pronouced effects on the phosphorylation and kinase activity of IKKa/b in the total and NEMO-immunoprecipitated IKKa/b fraction than on its changes at the protein level ( Figure 3E ). These results suggest that NLRC5 not only competes with NEMO for IKKa/b binding, but also inhibits IKKa/b phosphorylation and its ability to phosphorylate IkB or free IKKa/IKKb. To test this possibility, we performed experiments with constitutively active IKKa (SS176/180/EE) or IKKb (SS177/181/EE) mutants and found that NLRC5 interacted with constitutively active IKKa (EE) and IKKb (EE) (Figure S4D ). Kinase assays revealed that expression of NLRC5 inhibited the ability of IKKa (EE) and IKKb (EE) to phosphorylate IkB (i.e., 32p-GST-IkBa), as well as their ability to autophosphorylate IKK (i.e., 32p-IKK) ( Figure S4E ). These observations were further supported by NF-kB-luc assays showing that NLRC5 can inhibit NF-kB activation by the constitutively active IKKa (EE) and IKKb (EE) ( Figure S4F ). These results suggest that NLRC5 can inhibit the ability of active IKKa/IKKb to phosphorylate IkBa or free IKKa/IKKb.
To determine how NLRC5 inhibits the phosphorylation of IKK, we sought to identify the domain of IKKb responsible for interacting with NLRC5. Because NEMO is known to bind to the C terminus of IKKb (May et al., 2000) , we generated deletion mutants encompassing the amino-terminal kinase domain (KD), leucine zipper domain (LZ) and a C-terminal helix-loophelix (HLH) domain of IKKb, and tested them for their ability to interact with NLRC5 in an immunoprecipitation assay (Figure 3F ). Like the full-length IKKb, the IKKb-KD construct strongly interacted with NLRC5, while neither the IKKb-LZ nor the IKKb-HLH construct showed appreciable binding activity with NLRC5 ( Figure 3G ), indicating that NLRC5 specifically binds to the IKKb-KD domain. However, because of the large size of the NLRC5 protein, we considered that its binding to IKKb might physically block any binding of NEMO to IKK (Figures 3D and 3E) .
We next tested the specificity of NLRC5-mediated inhibition of IKK phosphorylation. As shown in Figures 3H and 3I , NLRC5 markedly inhibited the IKKa/b phosphorylation, but not p38 or JNK phosphorylation, consistent with the observation that NLRC5 did not interact with TAK1 or MEKK3 ( Figure S3A) . Finally, we further tested the status of the phosphorylation and kinase activity of IKKa/b in IKKa/b /NLRC5 and IKKa/b /NEMO complexes in RAW264.7 cells under physiological conditions. IKKa/b in the IKKa/IKKb/NLRC5 (NLRC5-IP) complex was not phosphorylated and showed no kinase activity during LPS stimulation. By contrast, IKKa/b in the IKKa/b /NEMO (NEMO-IP) complex was phosphorylated and exhibited a strong kinase activity after LPS stimulation ( Figure 3J ), suggesting that NLRC5 inhibits its phosphorylation and kinase activity in the IKKa/ IKKb/NLRC5 complex under physiological conditions. 
LRR Region Is Responsible for NLRC5-Mediated Inhibition of IKK Phosphorylation
To identify the functional domains of NLRC5, we generated four deletion constructs: NLRC5-D1, containing the CARD and NOD domains (aa 1-517); NLRC5-D2, containing the LRR-R1 (aa 651-898); NLRC5-D3, containing the linker region and LRR-R2 (aa 900-1329); and NLRC5-D4, containing the CARD domain and LRR-R3 (aa 1-215 plus 1471-1866) ( Figure 4A ). While all four NLRC5 deletion constructs could interact with the full-length IKKb protein as well as IKKb-KD ( Figures 4B and 4C ), NLRC5-D3, like the full-length NLRC5, strongly inhibited NF-kB-luc activity ( Figure 4D ). Other NLRC5 deletions showed either partial or no inhibitory effect on NF-kB-luc activity. These results suggest that NLRC5-D3 is required for the observed inhibition of NF-kB activity by NLRC5.
To further investigate the molecular mechanism by which NLRC5-D3 inhibits NF-kB activity, we tested whether these deletions can inhibit the phosphorylation of IKKa/b. We found that NLRC5-D3 strongly inhibited IKKa and IKKb phosphorylation, while NLRC5-D1, -D2 and -D4 produced little or weak inhibition ( Figure 4E) . Notably, the inhibitory activity of these NLRC5 deletion mutants on the phosphorylation of IKKa and IKKb correlated with their ability to inhibit NF-kB activation ( Figure 4D ), suggesting that NLRC5-D3 inhibits NF-kB activation by blocking the phosphorylation of IKK complexes. Unlike the full-length NLRC5, however, NLRC5-D3 failed to compete with NEMO for binding to IKKa/IKKb ( Figure S4G ), suggesting that the size of full-length NLRC5 is critical for its ability to physically block NEMO from interacting with IKKa/b.
Knockdown of NLRC5 Enhances NF-kB Activation as Well as the Inflammatory Response Since NLRC5 specifically interacts with IKKa/b and inhibits NF-kB activation, we reasoned that knockdown of NLRC5 would release IKKa/b for increased NF-kB activation under physiological conditions. To test this prediction, we first demonstrated the knockdown efficiency and specificity of NLRC5 or mNLRC5 at both the mRNA and protein levels in various cell types with at least two corresponding siRNAs, but not scrambled siRNAs ( Figure 5A and Figures S5A-S5C ). We next tested the effect of mNLRC5 knockdown on the phosphorylation of IKK, IkB, and other kinases, including JNK, ERK, and p38. As shown in Figure 5B and Figure S5D , the phosphorylation of IKK (p-IKK) and IkB (p-IkB) in the mNLRC5 knockdown cells was at least 3-fold higher than that in the scrambled siRNA-transfected (control) cells at 30 min after LPS treatment, although the total amounts of IKK and IkB proteins were comparable between mNLRC5 knockdown and control cells. More importantly, we did not observe any appreciable differences in p-JNK, p-ERK and p-p38 between mNLRC5 knockdown and control cells, clearly indicating the specific inhibitory effect of mNLRC5 on the phosphorylation of IKK, but not on JNK, ERK, and p38 phosphorylation. Similar results were obtained with human THP-1 cells (Figure S5E) . Collectively, these results suggest that specific knockdown of NLRC5 or mNLRC5 strongly enhances the phosphorylation of the IKK complexes, but does not affect the phosphorylation of JNK, ERK, and p38 after LPS stimulation.
To further determine the molecular mechanisms by which NLRC5 knockdown affects NF-kB signaling, we performed two-step immunoprecipitations to obtain NEMO-associated IKK (IP-1) and NEMO-free IKK (i.e., free IKK and NLRC5-associated IKK, IP-2) ( Figure 5C ) and then compared the amounts of IKKa/ IKKb in each complex and their phosphorylation (p-IKK) in mNLRC5 knockdown versus control cells. We found that the total IKKa/b proteins in the NEMO-free IKK fraction (i.e., IP-2) of mNLRC5 knockdown cells was slightly lower than that of control cells, while IKKa/b in the IKKa/b/NEMO fraction (i.e., IP-1) in mNLRC5 knockdown cells was slightly higher than that in control cells, suggesting that the reduction of IKKa/b /NLRC5 complex in mNLRC5 knockdown cells decreases the IKKa/b proteins in the NEMO-free IKK fraction, but increases the IKKa/b proteins in the NEMO/IKK complex ( Figure 5C ). Consistent with this observation, we found that the phosphorylation of IKK (p-IKK) in the NEMO-containing IP fraction (IP-1) in the mNLRC5 knockdown cells was higher than that in control cells. Importantly, even though the total IKKa/b in the NEMO-free fraction (IP-2) of mNLRC5 knockdown cells was less than that of control cells, its phosphorylation (p-IKK) level in mNLRC5 knockdown cells was higher than that in control cells ( Figure 5C ), suggesting that mNLRC5 knockdown reduces the inhibition of phosphorylation of free IKKa/b. This notion agrees with data, showing that NLRC5 interacts with constitutively active IKKa (EE) and IKKb (EE) and inhibits their phosphorylation and kinase activity ( Figures S4D and S4E) .
We next sought to determine whether the enhanced IKK phosphorylation seen with NLRC5 knockdown promotes NF-kB activation and NF-kB-dependent gene expression. Using the NF-kBluc reporter assay, we found that NLRC5 knockdown markedly increased NF-kB-luc activity in 293T/TLR4 and RAW264.7 cells after LPS treatment ( Figure 5D ). To directly demonstrate that mNLRC5 knockdown enhances endogenous NF-kB activity, we examined the DNA-binding activity of endogenous NF-kB. Results in Figure 5E show that endogenous NF-kB activity in mNLRC5 knockdown cells was at least 2-fold higher than that in control cells. Consistent with this observation, knockdown of NLRC5 or mNLRC5 resulted in markedly increased secretions of NF-kB-responsive cytokines, such as TNF-a and IL-6, in both mNLRC5 knockdown THP-1 and RAW264.7 cells ( Figure 5F ). Hence, knockdown of NLRC5 or mNLRC5 enhances the IKKa/b phosphorylation and NF-kB activity, thus increasing NF-kBdependent cytokine responses under physiological conditions.
NLRC5 Negatively Regulates Type I Interferon Signaling by Interacting with RIG-I and MDA5
Recent studies show that NLRX1 inhibits the RIG-I-mediated signaling pathway by targeting MAVS (Moore et al., 2008) . To determine whether NLRC5 might also be involved in the regulation of type I interferon signaling, we performed functional assays in TLR3-deficient 293T cells and found that intracellular poly(I:C) activated IFN-b signaling, although such activation was strongly inhibited by NLRC5 ( Figure 6A ), suggesting that NLRC5 functions as a negative regulator of this antiviral pathway.
To determine the molecular mechanisms by which NLRC5 could inhibit the IFN-b response, we performed similar experiments with different signaling molecules and found that RIG-Iand MDA5-induced IFN-b-luc activities could be markedly inhibited by increasing concentrations of NLRC5. However, NLRC5 weakly inhibited MAVS-and TBK1-induced IFN-b-luc activity and did not inhibit IKKi-induced IFN-b luciferase activity ( Figure 6A and Figure S6A ). Furthermore, NLRC5 markedly inhibited NF-kB-luc activity induced by intracellular poly(I:C), RIG-I, MDA5, MAVS or TBK1 ( Figure 6B ). To determine whether the weak inhibition of MAVS-and TBK1-induced IFN-b-luc activity by NLRC5 might be due to the inhibitory effect of NLRC5 on IKK complexes, but not due to any direct effect on MAVS or TBK1, we transfected 293T cells with ISRE-luc, together with RIG-I, MDA5, MAVS, or TBK1 in the presence or absence of NLRC5. Both RIG-I-and MDA5-induced ISRE-luc activities were potently inhibited, while MAVS-and TBK1-induced ISREluc activities were not ( Figure 6C ), suggesting that NLRC5 inhibits IFN-b activation by directly interacting with RIG-I and MDA5, but not with MAVS or TBK1. Indeed, we found that NLRC5 was strongly associated with RIG-I and MDA5, but did not interact with MAVS, IKKi, TBK1, TRIF, TRAF3, or IRF3 ( Figures 6D and  6E and Figure S6B ). Thus, NLRC5 specifically binds to the RIG-I and MDA5 proteins to inhibit the IFN-b response.
To further define the interaction between RIG-I and mNLRC5 under physiological conditions, we infected RAW264.7 cells with VSV-eGFP and performed immunoprecipitation with antimNLRC5 at different time points after VSV-eGFP infection. We detected only a weak RIG-I protein band in anti-mNLRC5 immunoprecipitants at 4 hr postinfection; however, it peaked at 6 hr and then became weak at 8 and 10 hr postinfection ( Figure 6F ). Notably, RIG-I protein expression was also increased at 6 hr postinfection ( Figure 6F ), consistent with previous observations (Honda and Taniguchi, 2006) . Importantly, IRF3 phosporylation was observed at 4 hr and further increased at 6 hr postinfection, indicating that VSV-eGFP infection activated the IRF3-dependent signaling pathway. However, IKK phosphorylation and IkB degradation were weak after VSV-eGFP infection ( Figure 6F ). These results suggest that interaction between NLRC5 and RIG-I is inducible after VSV-eGFP infection.
Because both the RIG-I protein level and IRF3 phosphorylation peaked at 6 hr postinfection, coincident with the peak interaction between mNLRC5 and RIG-I in RAW264.7 cells, we considered that this interaction might critically rely on activating signal. To test this possibility, we generated RIG-I-CARD and RIG-I-helicase constructs and tested their ability to interact with NLRC5. Interestingly, NLRC5 strongly bound to the CARD domain of RIG-I, but not to the helicase domain, while binding of NLRC5 to the CARD domain of RIG-I markedly exceeded that to the full-length RIG-I ( Figure 6G ), suggesting that the CARD domain becomes accessible only when RIG-I is activated by virusderived ligands. Furthermore, competition experiments revealed that NLRC5 strongly inhibited the ability of MAVS to bind to RIG-I ( Figure 6H ). Thus, it appears that the accessibility of the CARD domain of RIG-I is critical for a productive interaction between NLRC5 and RIG-I, and that such interaction may also be influenced by the relative concentrations of MAVS and NLRC5.
To confirm the inhibitory effect of NLRC5 on the IRF3 phosphorylation, we assessed the phosphorylation states of IRF3 by overexpressing NLRC5 in 293T cells and found that NLRC5 potently blocked the phosphorylation of endogenous IRF3 induced by RIG-I, but not by MAVS ( Figure 6I ). In contrast, NLRC5 or mNLRC5 knockdown in THP-1 and RAW264.7 cells markedly increased IRF3 phosphorylation ( Figure 6J ). Thus, NLRC5 can inhibit IFN-b signaling by blocking the binding of MAVS to RIG-I and the IRF3 phosphorylation.
Knockdown of NLRC5 Enhances Innate and Antiviral Immunity
To further demonstrate the effects of NLRC5 knockdown on the expression of IFN-responsive genes, we knocked down TNF-a, IL-6, IFN-a, and IFN-b . The data in (A-D) are reported as means + SEM of three independent experiments. Asterisks indicate significant differences between groups (*p < 0.05, **p < 0.01, ***p < 0.001 determined by Student's t test analysis). endogenous NLRC5 or mNLRC5 and then treated the cells with poly(I:C)/Lyovec or infected them with VSV-eGFP. Real-time PCR analysis revealed that poly(I:C)/Lyovec treatment or infection with VSV-eGFP strongly increased mRNA levels of IFN-b and the interferon-stimulating genes ISG54 and ISG56 in cells transfected with mNLRC5-or NLRC5-specific siRNAs ( Figure 7A and Figure S7A ), consistent with a previous study showing the upregulation of IFN-b mRNA in A549 cells with NLRC5 knockdown (Opitz et al., 2006) . Furthermore, we found that poly(I:C)/ Lyovec treatment or VSV-eGFP infection led to a large increase in the production of IFN-b protein in THP-1, RAW264.7, primary murine macrophages and primary human monocytes transfected with mNLRC5 or NLRC5-specific siRNA ( Figures 7B and  7C and Figure S7B ). We next determined their expression patterns over time after stimulation or VSV infection, and found that the NF-kB-responsive genes TNF-a and IL-6 in mNLRC5-knockdown cells were upregulated as early as 2-4 hr after LPS treatment, and IL-6 continued in that state for another 10 hr ( Figure 7D) . No difference was found between mNLRC5 knockdown and control cells, with the exception of IFN-b expression at 8 hr after LPS treatment ( Figure 7D ). Similar experiments with intracellular poly(I:C) treatment or VSV infection showed strong upregulation of IRF3-responsive IFN-a and IFN-b expression, but little or no effect on TNF-a and IL-6 expression ( Figure 7D ). Consistent with these observations, we found that LPS treatment resulted in more IL-6 and TNF-a than IFN-b protein, while VSV-eGFP infection led to more IFN-b than TNF-a and IL-6 proteins in mNLRC5 knockdown RAW264.7 cells ( Figure S7C ). It appears that stimulation with LPS leads to more pronounced effects on NF-kB-regulated genes than does either poly(I:C) treatment or VSV-eGFP infection, while the converse is seen for IRF-3-regulated genes.
To demonstrate a link between increased innate cytokine responses and antiviral immunity in NLRC5-silenced cells, we showed that knockdown of endogenous NLRC5 or mNLRC5 rendered cells remarkably resistant to viral infection and reduced the levels of VSV-eGFP-positive cells among 293T, THP-1, and RAW264.7 cells, as well as MEFs and human monocytes (Figure 7E and Figure S7D ). To monitor VSV-eGFP propagation in both mNLRC5 knockdown and control cells, we performed time course experiments and showed that GFP expression from VSV-eGFP could be observed at 8 hr postinfection with rapid propagation at 10 hr in control cells. More than 90% of the cells were GFP positive at 12 hr. By contrast, GFP expression from VSV-eGFP viruses could rarely be observed at 10 hr, became visible at 12-14 hr, and remained limited to a few cells even at 18 hr in mNLRC5-silenced cells ( Figure S7E ). At 15 hr, the morphology of the cells was markedly changed in control cells, but not in mNLRC5 knockdown cells ( Figure S7F ). At 20 hr, most of the cells in control group had died with a striking reduction in the GFP signal, while the cells treated with mNLRC5 siRNA remained alive and appeared normal ( Figure S7G ). We conclude that NLRC5 knockdown can significantly increase innate cytokine production and antiviral immunity against VSVeGFP infection and propagation.
DISCUSSION
Activation of innate immune receptors (TLRs, NLRs, and RLRs) by their corresponding ligands initiates several key signaling pathways, leading to the production of proinflammatory cytokines, such as IL-6 and TNF-a, which in turn induce profound positive feedback for adaptive immune responses Honda and Taniguchi, 2006) . Increasing evidence indicates that many inflammation-associated diseases may result from dysregulated innate immunity (Inohara et al., 2005; Ting et al., 2006) . More recently, IL-1, IL-6, and TNF-a produced by innate immune cells in chronic inflammation conditions have been shown to promote cancer development and progression . Thus, an understanding of the molecular mechanisms by which innate immunity is held in check through negative regulators appears critical for developing novel and more effective treatments for inflammation-induced autoimmune diseases and cancer .
Both NF-kB and type I interferon signaling are controlled at multiple levels by distinct mechanisms, whose regulatory proteins may themselves be direct transcriptional targets of NF-kB and type I interferon signaling, contributing to a negative regulatory feedback loop (Komuro et al., 2008) . For example, expression of the A20, CYLD, and DUBA negative regulators is controlled by NF-kB activity, while the RIG-I and MDA5 genes are transcriptionally regulated by type I interferon signaling (Komuro et al., 2008) . We similarly observed the upregulation of NLRC5 or mNLRC5 at both the mRNA and protein levels after 6 hr of treatment with LPS. Such upregulation was abolished in MyD88-deficient macrophages, suggesting that expression of NLRC5 itself is under the control of MyD88-NF-kB pathways and forms a negative regulatory feedback loop.
It has been demonstrated that the deubiquitinating enzymes A20 and CYLD inhibit NF-kB signaling by targeting TRAF6 upstream of IKK (Kovalenko et al., 2003; Liew et al., 2005; Trompouki et al., 2003; Wertz et al., 2004) , while the deubiquitinating protein DUBA inhibits type I interferon activity by targeting TRAF3 (Kayagaki et al., 2007) . Despite the importance of IKK as a central transducer of signaling from cytokines, TLRs and RLRs, leading to NF-kB activation, relatively little is known about its negative regulation. Our findings show that NLRC5 blocks IKK phosphorylation and thus NF-kB activation by interacting with IKKa and IKKb, but not with the regulatory subunit NEMO. To elucidate the mechanism(s) by which NLRC5 inhibits IKK function, we provide evidence that NLRC5 forms a large complex with IKKa/b, in addition to the previously described stable IKKa/b/NEMO complex that seems to be dominant in unstimulated cells (Rothwarf et al., 1998) . The interaction between NLRC5 and IKKa/b appears to be dynamic during the early phase (1-2 hr) of LPS stimulation and correlates inversely with A recent study shows that CUEDC2 interacts with IKKa/b, but not NEMO, and recruits PP1c to deactivate the IKK complex by dephosphorylating IKKa/b . In resting cells, CUEDC2 binds to IKKa/b (but not NEMO) and undergoes transient disassociation and reassociation steps after TNF-a treatment , similar to the interaction we described between NLRC5 and IKKa/b after LPS stimulation. We also show that IKKa/b in the IKKa/b /NLRC5 complex is not phosphorylated and lacks kinase activity, in contrast to IKKa/b in the IKKa/ IKKb /NEMO complex ( Figures 3E and 3J ). These studies clearly indicate that besides NEMO, other important regulatory proteins such as NLRC5 can control the phosphorylation and kinase activity of IKK complex through sequestering active IKKa/b.
Although the kinase domain of IKKb specifically recognized by NLRC5 differs from the NEMO-binding site at the C terminus of IKKb (May et al., 2000) , we show that NLRC5 physically blocks the binding of NEMO to IKKa/b due to its large size ( Figure 3E and Figure S4G ). Our results also show that NLRC5 can interact with constitutively active forms of IKKa (EE) and IKKb (EE) and inhibit their ability to phosphorylate IkBa, as well as their ability to autophosphorylate IKK ( Figures S4D and S4E) . Importantly, experiments with two-step immunoprecipitation provide further evidence that mNLRC5 knockdown has striking effects on IKK and NF-kB signaling ( Figure 5C ), probably through a modulating dynamic balance between /IKKa/b/NLRC5 and /IKKa/b/NEMO complexes as well as sequestering the active IKKa/b to form an inactive IKKa/b/NLRC5 complex. Furthermore, it has been suggested that the phosphorylation of Ser740 in IKKb and Ser68 in NEMO by active IKK may disrupt the interaction between IKK and NEMO (Hayden and Ghosh, 2008) , thus allowing other proteins, including NLRC5 or phosphatases, to interact with active IKK and terminate NF-kB signaling. These studies suggest that NLRC5 plays a critical role in inhibiting the phosphorylation and kinase activity of IKKa/b in NF-kB activation after LPS stimulation.
RIG-I and MDA5 are key receptors for triggering type I interferon signaling pathways, and are controlled by positive and negative regulators, such as TRIM25 and RNF125, through ubiquitination (Arimoto et al., 2007; Gack et al., 2007) . To test the hypothesis that other proteins are involved in the regulation of RLRs, we present evidence showing that NLRC5 can bind to both RIG-I and MDA5 but not to their downstream signaling molecules such as MAVS, TBK1, IKKi, TRAF3, or IRF3. These findings support a dual regulatory role for NLRC5 that encompasses both NF-kB and type I interferon signaling. Importantly, our results show that NLRC5 binds more strongly to the CARD domain of RIG-I than to the full-length RIG-I, suggesting that NLRC5 specifically recognizes the CARD domain when it becomes accessible after viral infection or stimulation by its ligands. This interpretation agrees with the proposed model for RIG-I action, in which the CARD domain of inactive RIG-I is masked by its intramolecular binding with the repressor domain in the C terminus (Cui et al., 2008; Yoneyama and Fujita, 2009 ). Once RIG-I is activated, the CARD domain is exposed for binding to MAVS or NLRC5.
Based on the experimental data discussed above, we propose a model to illustrate how NLRC5 could negatively control both NF-kB and type I interferon signaling ( Figure 7F) . First, the expression of NLRC5 itself is controlled by NF-kB activation, thus forming a negative regulatory feedback loop. Second, the key to modulating the activation of NF-kB by NLRC5 in stimulated cells lies in the dynamic balance between NLRC5/IKKa/ IKKb and NEMO/IKKa/IKKb complexes, which is controlled by signaling stimulation and relative protein (NLRC5 versus NEMO) concentrations, as well as the ability of NLRC5 to inhibit IKK phosphorylation and kinase activity by sequestering active IKKa/IKKb during signaling amplification after LPS stimulation. Thus, the striking effects of NLRC5 on NF-kB signaling and its downstream cytokine target genes cannot be explained by only a small fraction of the NLRC5/IKKa/IKKb complex being in an unstimulated state. Third, in contrast to its regulation of NF-kB activation, NLRC5 competes with MAVS for binding to the CARD domain of RIG-I or MDA5 only after it is exposed by ligand stimulation of these receptors, leading to dampened activation of IRF3. The interaction between NLRC5 and RIG-I is inducible after poly (I:C) treatment or VSV viral infection. Although TLR activation, cytokine stimulation and viral infection can activate both NF-kB and type I signaling pathways, but they tend to have a much more pronounced effect on either NF-kBregulated genes (e.g., LPS stimulation) or IRF3-regulated genes (poly(I:C) or VSV infection). This selectivity appears to reflect the different mechanisms by which NLRC5 regulates IKK activity or RIG-I/MDA5 proteins. The ultimate outcome of NLRC5 inhibition is determined by whether target gene promoters require NF-kB, IRF3, or both transcription factors for gene expression.
Finally, we show that specific knockdown of NLRC5 not only enhances NF-kB and type I interferon signaling and expression of their target genes, but also increases antiviral immunity in multiple cell lines and primary cells. Because of the conserved biological function of NLRC5 in humans and mice, as well as in various cell types, it appears to play a physiologically important role in the maintenance of immune homeostasis, especially with regard to regulation of the innate immune responses. Hence, NLRC5 may provide a useful therapeutic target for enhancing immunity against microbial infections and inflammation-associated diseases.
EXPERIMENTAL PROCEDURES Molecular Cloning of Full-Length Human and Mouse NLRC5
A full-length NLRC5 cDNA was obtained from human PBMC cDNA by twostep PCR and was then cloned into pcDNA3.1Z with HA tag sequence.
A similar strategy was used to clone mouse NLRC5. Both pcDNA-HA-NLRC5 and pcDNA-HA-mNLRC5 were sequenced to verify the correct DNA sequence and their open reading frames.
Expression Profile and Antibody Production
The expression profile of NLRC5 and mNLRC5 in different tissues was evaluated by reverse transcriptase (RT)-PCR analysis. NLRC5 and mNLRC5 peptides were used to generate polyclonal antibodies by standard methods.
Luciferase Assays, Immunoblot, Immunoprecipitation, and Kinase Assay HEK293 cells were transfected with IFN-b, NF-kB, or ISRE luciferase plasmids and HA-NLRC5. TNF-a, IL-1b, LPS as well as exogenous MyD88, TRAF6, IKKa, IKKb, NEMO, , RIG-I, MDA5, MAVS, and IKKi plasmids were used as stimulators. Dual-luciferase kits (Promega) were used for subsequent analysis. For kinase assay, a fusion of glutathione S-transferase and amino acids of 1-54 of IkBa (GST-IkBa) was used as the substrate. To determine the kinase activity of immuoprecipitated IKKa (EE) and IKKb (EE) to autophosphorylate IKK, we added 32 p-ATP to immunoprecipitatants and incubated the mixture at 30 C for 30 min. 32 p-GST-IkBa (*p-GST-IkBa) and 32 p-IKK (*p-IKK) were detected by autoradiography.
Protein Fractionation by Size-Exclusion Column
Cell extracts prepared from RAW264.7 cell with lysis buffer were centrifuged at 20,000 rpm for 20 min at 4 C. Fifteen mg of protein in a volume of 1.5 ml was loaded onto a size-exclusion column (HiPrep 16/60 Sephacryl S-300 HR) with the capacity to separate the large protein complexes. Samples were fractionated with a flow rate of 0.5 ml per min, and collected as 0.5 ml fractions after passage through the void volume. Protein fractions were separated by SDS-PAGE and detected by western blotting with antibodies against mNLRC5, IKKa/b, or NEMO.
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assays were performed by using the LightShift Chemiluminescent EMSA kit from Pierce Biotechnology according to the manufacturer's standard protocol.
Real-Time PCR Analysis
First-strand cDNA was generated from total RNA using oligo-dT primers and reverse transcriptase (Invitrogen). Real-time PCR was conducted with the QuantiTect SYBR Green PCR Master Mix (QIAGEN) and specific primers on an ABI Prism 7000 analyzer (Applied Biosystems).
Knockdown of NLRC5 and mNLRC5 by RNA Interference NLRC5-specific, mNLRC5-specific and control (2-scramble mix) siRNA oligonucleotides were obtained from Invitrogen and Integrated DNA Technologies, and transfected into 293T, THP-1, RAW264.7 and primary cells with use of Lipofactamine 2000 (Invitrogen) and various Nucleofector kits (one for each cell type) according to the manufacturer's instruction.
Statistical Analysis
The results of all quantitative experiments are reported as mean ± SEM of three independent experiments. Comparisons between groups for Statistical Significance were performed with a two-tailed paired Student's t test.
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